Abstract
ALTHOUGH the biological basis of schizophrenia is not known, possible causes include genetic defects, viruses1, amines2, brain structure and metabolism3–5, neuroreceptors6–8, and G proteins9. The hypothesis of dopamine overactivity in schizophrenia is based on the fact that neuroleptics block dopamine D2 receptors in direct relation to their clinical antipsychotic potencies10–11. Moreover, dopamine D2 or D2-like receptors are elevated in postmortem schizophrenia brain tissue8,12,13. This elevation, however, is only found in vivo using [11C]methylspiperone14 but not [11C]raclopride15. The dopamine D4 receptor gene16 has not yet been excluded in schizophrenia because the 21 gene variants17 of D4 have not yet been tested. Because the link between Dl and D2 receptors is reduced in schizophrenia tissue9, we tested whether one component of this link was sensitive to guanine nucleotide. We report here that the binding of [3H]raclopride to D2 receptors in schizophrenia was not sensitive to guanine nucleotide. This finding permitted analysis of data12,18 on the binding of [3H]emonapride to the D2, D3 and D4 receptors. We conclude that the combined density of D2 and D3 receptors (labelled by [3H]raclopride16,19) is increased by only 10% in schizophrenia brain, as found by Farde et al.15, but that it is the density of dopamine D4 receptors which is sixfold elevated in schizophrenia. These findings resolve the apparent discrepancy, mentioned above, wherein the density of [11C]methylspiperone-labelled sites14 (D2, D3 and D4), but not that of [11C]raclopride-labelled sites15 (D2 and D3), was found elevated in the schizophrenia striatum.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Carter, G. I., Taylor, G. R. & Crow, T. J. J. Neurol. Neurosurg. Psychiat. 50, 247–251 (1987).
Spokes, E. G. S., Garrett, N. J., Rossor, M. N. & Iversen, L. L. J. neurolog. Sci. 48, 303–313 (1980).
Andreasen, N. C. Science 239, 1381–1388 (1988).
Suddath, R. L., Christison, G. W., Torrey, E. F., Casanova, M. F. & Weinberger, D. R. New Engl. J. Med. 322, 789–794 (1990).
Buchsbaum, M. S. et al. Arch. gen. Psychiat. 49, 935–942 (1992).
Crow, T. J. et al. in Enzymes and Neurotransmitters in Mental Disease (eds Usdin, E., Sourkes, T. L. & Youdim, M. B. H.) 559–572 (Wiley, New York, 1980).
Meltzer, H. Y. Schizophrenia Bull. 17, 263–287 (1991).
Lee, T., Seeman, P., Tourtellotte, W. W., Farley, I. J. & Hornykiewicz, O. Nature 274, 897–900 (1978).
Seeman, P., Niznik, H. B., Guan, H.-C., Booth, G. & Ulpian, C. Proc. natn. Acad. Sci. U.S.A. 86, 10156–10160 (1989).
Seeman, P., Wong, M. & Lee, T. Fedn Proc. 33, 246 (1974).
Seeman, P., Chau-Wong, M., Tedesco, J. & Wong, K. Proc. natn. Acad. Sci. U.S.A. 72, 4376–4380 (1975).
Seeman, P. et al. Neuropsychopharmacology 1, 5–15 (1987).
Seeman, P. Neuropsychopharmacology 7, 261–284 (1992).
Wong, D F. et al. Science 234, 1558–1563 (1986).
Farde, L. et al. Arch. gen. Psychiatry 47, 213–219 (1990).
Van Tol, H. H. M. et al. Nature 350, 610–614 (1991).
Lichter, J. B., Livak, K. J., Rogers, J., Kennedy, J. L. & Van Tol, H. H. M. Nature 360, 424 (1992).
Seeman, P., Guan, H.-C., Van Tol, H. H. M. & Niznik, H. B. Synapse 14, 247–253 (1993).
Sokoloff, P., Giros, B., Martres, M.-P., Bouthenet, M.-L. & Schwartz, J.-C. Nature 347, 146–151 (1990).
Seeman, P., Guan, H.-C. & Niznik, H. B. Synapse 3, 96–97 (1989).
Seeman, P., Ulpian, C., Wreggett, K. A. & Wells, J. J. Neurochem. 43, 221–235 (1984).
Lazareno, S. J. Receptor Res. 3, 163–175 (1983).
George, S. R., Watanabe, M. & Seeman, P. J. Neurochem. 44, 1168–1177 (1985).
Seeman, P. & Niznik, H. B. ISI Atlas Sci. Pharmac. 2, 161–170 (1988).
Seeman, P. & Schaus, J. M. Eur. J. Pharmac. 203, 105–109 (1991).
Battaglia, G., Shannon, M. & Titeler, M. J. Neurochem. 43, 1213–1219 (1984).
Ezrin-Waters, C., Seeman, M. V. & Seeman, P. J. clin. Psychiat. 42, 16–22 (1981).
Seeman, P. et al. Eur. J. Pharmac. molec. Pharmac. Sect. 227, 139–146 (1992).
Wreggett, K. A. & Seeman, P. Molec. Pharmac. 25, 10–17 (1984).
Seeman, P., Ulpian, C., Grigoriadis, D., Pri-Bar, I. & Buchman, O. Biochem. Pharmac. 34, 151–154 (1985).
Van Tol, H. H. M. et al. Nature 358, 149–152 (1992).
Hall, H., Halldin, C. & Sedvall, G. Neurosci. Lett. 136, 79–82 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Seeman, P., Guan, HC. & Van Tol, H. Dopamine D4 receptors elevated in schizophrenia. Nature 365, 441–445 (1993). https://doi.org/10.1038/365441a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/365441a0
This article is cited by
-
Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications
Molecular Psychiatry (2022)
-
The neurochemical pathology of schizophrenia: post-mortem studies from dopamine to parvalbumin
Journal of Neural Transmission (2022)
-
Reduced GABA/glutamate in the thalamus of individuals at clinical high risk for psychosis
Neuropsychopharmacology (2021)
-
Structural signatures of DRD4 mutants revealed using molecular dynamics simulations: Implications for drug targeting
Journal of Molecular Modeling (2016)
-
Enhancement of gamma activity after selective activation of dopamine D4 receptors in freely moving rats and in a neurodevelopmental model of schizophrenia
Brain Structure and Function (2014)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.